Figure 2 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

PFS according to clinical subgroups. Kaplan–Meier estimates of PFS in patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months who, at screening, had the presence of (A) bone metastases (n = 136; 86%); (B) liver and/or lung metastases (n = 113; 71%); (C) n = 82; 52%); or (D) ≥3 metastatic sites (n = 53; 33%). aEighty-five percent of patients had bone and other sites of metastases (30% of these patients had no liver or lung involvement). bFifty-five percent of patients had liver and other sites of metastases (10% of these patients had no lung or bone involvement); 25% of patients had lung and other sites of metastases (2% of these patients had no liver or bone involvement). cThe number of metastatic sites was available for 135 of 159 patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months.